Freenome, Inc. Common stock

Freenome, Inc. Common stock(FRNM)價格預測

$13.040

+0.329 (+2.52%)收盤時

價格預測

1-Day Price Prediction
+1.90%
1-Week Prediction
+7.44%
1-Month Prediction
—
2026 Prediction
—
2030 Prediction
—

在 App 中開啟以解鎖更長週期的預測。

Loading chart…

FRNM 相似圖表分析預測

Alphio's FRNM stock price prediction model matches the current Freenome, Inc. Common stock tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $13.29 (+1.90%). The 1-week path is $14.01 (+7.44%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

該買進 Freenome, Inc. Common stock 股票嗎?

Freenome, Inc. is a good buy right now due to its recent FDA approval for a colorectal cancer screening test, which has driven a 5% increase in stock price and indicates strong future revenue potential. The current price is $12.77, significantly below the analyst price target of $21, suggesting a potential upside of 64%. Additionally, the stock has shown a recent 5-day change of +8.68%, indicating positive momentum. However, a risk to consider is the negative net income reported for Q4 2025 at -740568.00 USD, which highlights ongoing financial challenges that could affect performance in the near term.

FRNM 股價於 Tuesday 收在 $13.04,此前上漲 +2.52%

Freenome, Inc. Common stock (FRNM) last closed at $13.04, gaining +2.52%. These facts feed the 1-day and 1-week FRNM price prediction above.

預測驅動因素

Freenome, Inc. Common stock(FRNM)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。

Similar patterns

Positive

Bullish

Seasonality

Positive

Bullish

SMA 20

Negative

Bearish

SMA 200

Negative

Bearish

相似圖表形態

近期走勢與 FRNM 最接近的股票,依相似度排序。

FRNM 季節性分析

Loading chart…

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易